Login / Register Submit Your Article
cover
Journal of Public Health & Environment

Volume 3, 2020 - Issue 2

Submit Manuscript Journal Homepage
Latest Issue
Input keywords, title, abstract, author, affiliation etc..
Article Menu
Browse this journal
Vol. 8 (2025)
Vol. 7 (2024)
Vol. 6 (2023)
Vol. 5 (2022)
Vol. 4 (2021)
Vol. 3 (2020)
Vol. 2 (2019)
Vol. 1 (2018)
Updates more >>
1 February 2024 Journal of Public Health & Environment Honors Exceptional Reviewers with 2023 Best Reviewer Awards
1 June 2023 Statement on Supporting the Use of GPT Models in Research
1 March 2023 Journal of Public Health & Environment Honors Distinguished Reviewer of 2022
31 January 2022 Best Reviewer Award for 2021
5 February 2020 Call for Papers: Special Issue 2020
Cooperative Partner

 

  

Journal Article An open access journal
Journal Article

Immunotherapy in Cancer Treatment: Harnessing the Immune System's Power

by Aria Reed 1,*
1
Universidade Federal de Goiás
*
Author to whom correspondence should be addressed.
JPHE  2020 3(2):54; https://doi.org/10.xxxx/xxxxxx
Received: 31 August 2020 / Accepted: 29 September 2020 / Published Online: 8 December 2020
View Full-Text
Download PDF

Abstract

Immunotherapy has emerged as a revolutionary approach in cancer treatment, capitalizing on the immune system's inherent ability to recognize and eliminate cancer cells. This paper explores the principles and mechanisms underlying immunotherapy, including immune checkpoint inhibitors, adoptive cell transfer, and therapeutic vaccines, in the context of cancer treatment. Key topics include the rationale for immunotherapy, patient selection criteria, and the management of immune-related adverse events. Additionally, the paper discusses recent clinical trials and breakthroughs in immunotherapy across various cancer types, highlighting durable responses and improved survival outcomes observed in patients. Furthermore, the paper examines challenges associated with immunotherapy, such as treatment resistance and biomarker identification, and discusses ongoing efforts to optimize treatment strategies and combination therapies. By synthesizing evidence from preclinical models and clinical studies, this paper aims to elucidate the promise and challenges of harnessing the immune system's power in the fight against cancer.

Keywords: immunotherapy; cancer treatment; immune checkpoint inhibitors; adoptive cell transfer.;
Copyright: © 2020 by Reed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Share and Cite

ACS Style
Reed, A. Immunotherapy in Cancer Treatment: Harnessing the Immune System's Power. Journal of Public Health & Environment, 2020, 3, 54. doi:10.xxxx/xxxxxx
AMA Style
Reed A. Immunotherapy in Cancer Treatment: Harnessing the Immune System's Power. Journal of Public Health & Environment; 2020, 3(2):54. doi:10.xxxx/xxxxxx
Chicago/Turabian Style
Reed, Aria 2020. "Immunotherapy in Cancer Treatment: Harnessing the Immune System's Power" Journal of Public Health & Environment 3, no.2:54. doi:10.xxxx/xxxxxx

Article Metrics

Article Access Statistics

References

  1. Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711-723.
  2. Topalian, S. L., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443-2454.
  3. June, C. H., et al. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.
  4. Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69-74.
  5. Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61.
  6. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355.
  7. Postow, M. A., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine, 372(21), 2006-2017.
  8. Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature, 541(7637), 321-330.